Hemorrhagic Shock and Massive Abdominal Wall Hematoma After Cesarean Section in a Patient with Peripartum Acquired Hemophilia A:A Case Report.

Estimating the Impact of Hemophilia A Treatment Administration on Patient Health Utility: Combining a Discrete Choice Experiment with Time Trade-Off Method.

Clinical Experience with Emicizumab and Rituximab as First-Line Treatment in a Case Series of Acquired Hemophilia A.

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

Postpartum Acquired Hemophilia A in Two Women With Previously Undiagnosed Carrier Status for von Willebrand Disease Type 2N and Heterozygous p.R854Q Mutation.

Case Report: Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time.

ABO blood group-mediated VWF kinetics associated with early phenotypic divergence in dizygotic twins with severe hemophilia A.

Investigation of kinesiophobia, physical activity, quality of life, depression and anxiety level in adult people with hemophilia: A frequency-matched case-control study.

In Vitro Stability Study Supports the Use of Efmoroctocog Alfa and Rurioctocog Alfa Pegol for Continuous Infusion in Hemophilia A.

FIXa-triggered thrombin generation correlates with FVIII levels less than 1% in reconstituted plasma mimicking samples obtained from patients with severe hemophilia A.

Delayed diagnosis of acquired hemophilia a complicating hepatocellular carcinoma: a rare case of hepatectomy following atezolizumab and bevacizumab therapy.

Acute recurrent appendicitis in a hemophiliac Nepalese girl: beyond just… avoidance of formidable cuts! - A case report.

New Methods for Activated Partial Thromboplastin Time -Based Clot Waveform Analysis: Normalization and Multi-Parameter Combination.

An analysis of attitudes toward gene therapy in people with severe hemophilia in Germany, a survey-based cross-sectional study.

Deleterious NKAP Mutations Are Associated with Musculoskeletal Abnormalities in Hemizygous Males and Skewed X Chromosome Inactivation in Heterozygous Females.

Genotype-Specific Postural Control Deficits in Hemophilia A: Insights from Center of Pressure Analysis Beyond Radiographic Arthropathy.

Psychosocial Outcomes and Quality of Life in Patients with Hemophilia a Without Inhibitors: The HemoLIFE Study.

Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis.

Mechanisms of thrombin inhibition by protein S and the TFPIα-fVshort-protein S complex.

In Vitro Spiking Comparison of Coagulation Potential Between Emicizumab and Mim8 in Whole Blood and Plasma From a Single Patient With Severe Hemophilia A Receiving FVIII Prophylaxis and Warfarin.

Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels.

Persons with high Hemophilia Joint Health Scores have reduced functional range of motion during simulated sports activities.

[Acquired hemophilia A secondary to marginal zone lymphoma].

Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity.

Monochorionic diamniotic twin brothers with severe hemophilia A: a case report.

Comprehensive Care for People With Hemophilia: A Dental Perspective From an Indian Scenario.

Subclinical Cardiac Diseases and the Role of Extracellular Vesicles in Patients with Hemophilia A Treated on-Demand.

A Case of Acquired Hemophilia A Following Robot-Assisted Minimally Invasive Esophagectomy.

A combinatorial CAAR-T cell strategy to eliminate factor VIII inhibitors in preclinical models of hemophilia A.

Enhanced Peripartum Hemostatic Management Does Not Decrease Postpartum Hemorrhage Incidence in Hemophilia Carriers: the Pregnancy and Inherited Bleeding Disorders study (PRIDES).

Development of a Novel Hemophilia A Mouse Model to Study Emicizumab and Factor VIII Inhibitor Risk.

Kinesiophobia in Parents of Children with Haemophilia.

Discrepancies of results for post infusion levels of extended half-life factor VIII/IX concentrates - a cause of concern, awaiting for solution.

Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. on-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials.

Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.

COVID-19-Associated Acquired Hemophilia A With an Exceptionally High Inhibitor Titer: A Case of Remission and Overwhelming Sepsis.

Immune Response Associated Hepatotoxicity in Hemophilia Gene Therapy: Mechanisms, Management, and Challenges.

Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience.

Machine learning estimation of FVIII pharmacokinetic parameters in Chinese children with severe Hemophilia A.

Is marstacimab the next step in personalized and effective haemophilia management?

Association of Patient-Reported Outcomes with Hemophilia A Inhibitor Status and Treatment Product Type.

Managing massive gastrointestinal and abdominal haemorrhage in inherited bleeding disorders: experience from a pediatric cohort.

Two decades of prenatal diagnosis in hemophilia A and B: a systematic review of global trends and current practices.

Pathogen-Reduce Cryoprecipitate: An Overview of Method(s) in Pathogen Reduction, Transfusion-Transmitted Infection Risk, and Inventory Management Considerations.

Understanding Treatment Care and Delays in Acquired Hemophilia A: A Population-Based Study From Nova Scotia, Canada.

Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.

Health Related Quality of Life (HRQoL) and the Factors Affecting it in Children with Hemophilia.

Pharmacokinetics of Factor VIII in Adults with Hemophilia: A 24-Hour Single-Sample Study Focused on Trough Levels.

Exercise Programmes for People With Haemophilia: A Scoping Review.

GTH 2026: Connected Science - Advanced Solutions.

A Multifactorial Case of Acquired Hemophilia A.

Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis.

Corrigendum to 'Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors': [Research and Practice in Thrombosis and Haemostasis Volume 9, Issue 6, August 2025, 103006].

Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays.

Thrombin Generation Assays: Possibilities and Limitations.

Immune Response Mechanisms in Haemophilia A.

Gene Therapy of Haemophilia: Current Status and Future Directions.

Severe hemophilia A with inhibitors and pancreatic cancer - when emicizumab is not enough.

Twelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A.

A chemiluminescent microfluidic thrombin generation assay for real-time monitoring in patient plasma.

MLDP-AS: an optimized next-generation sequencing assay for enhanced detection of technically challenging variants in expanded carrier screening.

Country-level prediction of blood type distribution in hemophilia A in support of factor VIII consumption.

Challenges in Balancing Hemostasis and Thrombosis in Therapy Tailoring for Hemophilia: A Narrative Review.

Enhancing Hemophilia A Care Through Home-Based Prophylaxis: Real-World Outcomes of a National Patient Support Program in Mexico.

Postpartum acquired hemophilia presenting as compartment syndrome: a diagnostic challenge in the emergency department.

Integrative modeling to improve bleeding risk prediction in adult female hemophilia A carriers.

A Revised Classification of FVIII Concentrates: Rationale and Novel Metrics.

FVIII-containing platelets modulate immune responses and attenuate inhibitor development in hemophilia A mice.

Impact of prophylaxis, inhibitors, and genetics on joint outcomes according to the IPSG-MRI score in hemophilia A, B and vWD type 3.

Clinical Spectrum, Subtype Distribution, and Treatment Outcomes in von Willebrand Disease: A Prospective Study from a Hemophilia Treatment Center in Pakistan.

Mutations of six amino acid residues in a B domain-deleted blood coagulation factor VIII have a cumulative effect on increasing its secretion.

TNF‑α Gene Polymorphisms as Determinants of Alloantibody Emergence in Hemophilia: A Systematic Review and Meta-Analysis.

Factors contributing to the development of hemophilic arthropathy: A real-world study.

A first-in-human study assessing the safety, pharmacokinetics, and pharmacodynamics of TU7710, a recombinant factor VIIa-transferrin fusion protein, in warfarin-pretreated healthy male participants.

Monitoring the Hemostatic Balance: measuring thrombin generation in a patient with acquired hemophilia A on combined pro- and anticoagulant therapy.

rFVIIIa-platelet binding enhances platelet procoagulant activity independently of thrombin generation.

Human leukocyte antigen alleles associated with inhibitor development in severe hemophilia A: analysis of the "My Life, Our Future" hemophilia A cohort.

The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.

NXTAGE: a phase 1/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors.

A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase I/II trials.

Real-world adherence to and persistence with emicizumab in people with hemophilia A using a national claims database.

Factor VIII originates primarily from anatomically distinct subsets of liver sinusoidal endothelial cells.

Frequency of T Regulatory Cells Subpopulations in Hemophilia A Patients with Inhibitors.

A Case Report on Emergency Medicine: Suspected Acquired Hemophilia A in an Older Adult Male.

Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X.

Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay.

Corrigendum to "Real-world safety and effectiveness of rurioctocog alfa pegol in 338 patients with hemophilia A in South Korea: A postmarketing surveillance study" [Thromb. Res. 253 (2025) 109402].

Evidence-based dental management strategies for individuals with congenital hemophilia: a systematic review.

Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis.

Sleep and Haemophilia-A Case-Control Analysis of Associated Factors.

Lifetime Cost-Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis.

Nine areas with outstanding challenges for hemophilia B research.

Coexistence of two X-linked disorders: hemophilia A and G6PD deficiency.

Complex Triple Deformity of the Knee Managed with Knee Arthrodesis in a Severe Hemophilia A Patient: A Case Report.

Treatment of canine hemophilia A via intraosseous delivery of a platelet-specific factor VIII-lentiviral vector.

Case Report: Intracranial hemophilic pseudotumor mimicking an aggressive neoplasm: a rare skull-invasive presentation.

Extraarticular and Intraarticular Key Lesions in Knee Joints of Adult Persons with Hemophilia-A Case-Control Ultrasound Study.

Acquired Hemophilia A After Neoadjuvant Immunotherapy for Renal Cell Carcinoma.

Key Findings From the World Federation of Haemophilia National Member Organization Survey on Women and Girls With Bleeding Disorders.

Transplanted gene-modified placental cells boost FVIII activity in pediatric sheep without eliciting immunity, toxicity, or adverse events.

Redefining hemophilia management: treatment goals, nonfactor replacement therapies, and the role of fitusiran.

Feasibility and outcomes of switching factor VIII therapies: post-hoc analysis of patients transitioning from older plasma-derived and first-generation recombinant factor VIII to newer third-generation recombinant factor VIII replacement therapies within the Takeda factor VIII portfolio.

Platelet function abnormalities in acquired hemophilia A.

The IL-33 receptor ST2 as a therapeutic target for hemophilic arthropathy.

On Factor VIII Assay Discrepancies in Post-infusion Samples Obtained from Patients Treated with Efanesoctocog Alfa.

Anti-emicizumab antibodies and their relevance in clinical practice.

Joint tissue plasticity in hemophilia: insights from the Joint Activity and Damage Exam ultrasound protocol.

Interfacility Collaboration for Hemophilia Care in Japan: A Retrospective Database Study Using a Japanese Healthcare Claims Database.

Balancing Promise and Peril: Hemophilia Gene Therapy Insights.

Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments.

Evaluation of the Burden of Bone Fractures in People Living With Haemophilia: A Registry-Based Matched Cohort Study.

Bridging the Gap: Efficacy of Low-Dose Emicizumab in Haemophilia A With or Without Inhibitors.

An Initial Diagnosis of Acquired Hemophilia A in an Elderly Male With a Neck Hematoma.

Health care resources and costs associated with delivering gene therapy for hemophilia in clinical practice.

Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study.

Emicizumab in Acquired Hemophilia A: A Real-World Case Series with Patient-Level Outcome Analysis.

Performance of Factor VIII Extended Half-Life Product Measurements in External Quality Assessment Programmes.

Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study.

Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry.

florio HAEMO-A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With Haemophilia.

Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice.

Immunogenicity of Gene and Cell Therapies.

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Engineering Liver-Specific Promoters: A Comprehensive Review of Design, Mechanisms, and Clinical Applications in Gene Therapy.

Characteristics and posttransplant outcomes of patients with congenital and acquired von Willebrand disease and hemophilia A and with renal transplants.

Characterization of a factor VIII/immunoglobulin heavy chain μ double-knockout mouse model of hemophilia A for long-term exposure to factor VIII proteins.

Efficacy of radiosynoviorthesis on clinical outcomes in persons with haemophilia. A systematic review and meta-analysis.

Noncarrier mothers of hemophilia A patients with Intron 22 inversions often have other rearrangements.

Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.

Massive Intra-Abdominal Pseudotumor in a Patient With Hemophilia A Treated With Emicizumab: A Case Report.

Remarkable Prolongation of Irreversible APTT and Non-Significant Hemorrhage: A Rare High Titer of FVIII Inhibitor Case Report and Literature Review.

Race, Ethnicity, and Hemophilia: A Scoping Review.

Barriers to dental care and parental attitudes toward oral health in children with haemophilia: a cross-sectional study in China.

mGem: AAV, from almost a virus to an awesome vector-or is it?

Post-Infectious Acquired Hemophilia A: A Case Report and Review of the Literature.

Season-dependent low basal CD86 expression promotes immune cell activation upon treatment with plasma-derived factor Ⅷ products.

Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study.

Real-World Diagnosis and Testing of Acquired Hemophilia A in Japan: A Web-Based Physician Survey.

Repeated hemorrhagic ulcers of the esophagus associated with acquired hemophilia A: A case report.

Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B.

A Deletion Variant of Human Factor VIII Displaying Low Immunogenicity in a Murine Model of Hemophilia A.

A Rare Case of Mild Hemophilia A in a Female with Mosaic Monosomy X and a De Novo F8 Variant.

Low-Load Quadriceps Strengthening With Blood Flow Restriction in Adults With Haemophilic Knee Arthropathy: A Randomised Controlled Trial.

Carotid Intima-Media Thickness as a Marker of Subclinical Atherosclerosis in Adolescents With Severe Haemophilia.

Five-Year Experience of Haemophilia Centre Certification Performed by the German, Austrian and Swiss Society for Thrombosis and Haemostasis Research.

von Willebrand disease combined with other hemostasis disorders: an overlooked clinical entity.

Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors.

Overview of gene therapy for hemophilia: questions and answers to navigate the innovation.

Recurrence of FVIII Inhibitor during Surgery in a Patient with Severe Hemophilia A Receiving Emicizumab Prophylaxis.

Successful hemodialysis initiation in acquired hemophilia a managed with susoctocog alfa and emicizumab.

High Prevalence of Heterotopic Ossification in Mild Hemophilia: A Biological Inevitability or a Prophylactic Blind Spot?

Inhibition of CIRBP as a Novel Strategy to Alleviate Chondrocyte Ferroptosis in Haemophilic Arthropathy.

Approaches to Identify People With Haemophilia With Medicare Claims Data.

Safe Outpatient Dental Management of a Pediatric Patient With Mild Hemophilia A: A Case Report.

Mixing Test in a Case of Combined Acquired Hemophilia A and Coagulation Factor Deficiency: A Case Report.

Laparoscopic Cholecystectomy for Acute Cholecystitis in a Patient with Acquired Hemophilia A: A Case Report of Perioperative Hemostatic Management with Plasma Exchange.

Acquired Hemophilia A in Sjögren's Syndrome: An Uncommon Bleeding Disorder Masked by Antiplatelet Use.

Current gynaecological management of women and girls with bleeding disorders in the United Kingdom: A UKHCDO haemophilia treatment centre survey and evaluation of real-world clinical practice for the British Journal of Haematology.

Orthopedic manifestations of acquired hemophilia: a case report on uncontrolled bleeding and progressive swelling post-phlebotomy- should fasciotomy be considered?

Hemophilic pseudotumor in the hand: a case report and literature review.

[How I treat acquired clotting factor deficiency].

Defining the critical roles of factor VIII residues 1900 to 1908 in factor VIIIa-factor IXa complex formation and factor VIIIa activity.

Acceptability and Determinants for Implementation of the EnzySystem, a Novel Near-Patient Testing Platform for Haemophilia A.

Integration of Efanesoctocog Alfa in Clinical Practice for Children, Adolescents, and Young Adults With Severe Haemophilia A.

T cells from individuals with and without hemophilia A respond to the same epitopes in factor VIII.

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors.

Outcomes of Emicizumab Treatment for Haemophilia A Paediatric Patients: A Systematic Review With Meta-Analysis.

Vildagliptin-Associated Acquired Hemophilia A.

Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center.

Eight-Week Resistance Training and Manual Therapy in Young Patients with Severe Hemophilia: A Case Series Evaluating Functional, Imaging, and Immunological Outcomes.

Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural study.

mRNA based in vivo MG1113 antibody production as a potential therapeutic approach for hemophilia.

Acquired Hemophilia A Following Omalizumab Treatment in a Patient With Chronic Spontaneous Urticaria.

AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis.

Osteonecrosis of Femoral Head with Antiphospholipid Syndrome and Acquired Subclinical Hemophilia A.

Heterogeneity of active mast cells, endothelial cells, and fibroblasts in hemophilic arthritis defined by synovial single-cell sequencing.

Dental Neglect by Individuals With Haemophilia: Clinical Challenges and Solutions.

Patient and Caregiver Preferences for Long-Term Prophylactic Treatment of Bleeds in Haemophilia: A Discrete-Choice Experiment.

Haemophilic Elbow Arthropathy: Mechanisms, Management and Future Perspectives.

Recurrent hemoptysis after laryngectomy-acquired hemophilia induced by laryngeal cancer surgery and chemoradiotherapy: A case report.

[A cohort study on cardiovascular diseases in adults with hemophilia: an interim subanalysis on comorbidities and medication from ADVANCE Japan].

Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.

Optimized production and coagulation activity of rhFVII in HEK293 cells for bleeding disorders.

The aging hemophilia patient.

New therapies in hemophilia: extend the half-life, mimic, or rebalance?

Deconstructing gene therapy in hemophilia for the clinician.

Cell and Gene Therapy: Transforming Treatment Paradigms for Patient-Centric Care.

Impact of Inhibitor Development on the Cost Effectiveness of Prophylactic Treatment with Recombinant Factor VIII in Previously Untreated Patients with Severe Hemophilia A.

Continuum of Care for Hemophilia: The Story of India.

Case Report of acupotomy release combined with manual release under anesthesia for adhesions after unilateral total knee arthroplasty in a patient with hemophilia A.

Critical limb ischemia leading to amputation as a presentation of acquired hemophilia A with congenital factor XII deficiency: a case report.

Selective embolization for recurrent gingiva bleeding associated with aneurysmal bone cyst and hemophilia: A case report.

Robot-assisted total hip arthroplasty following gene therapy for hemophilia a arthropathy: a case report.

Author Correction: Long-term correction of hemophilia A via integration of a functionally enhanced FVIII gene into the AAVS1 locus by nickase in patient-derived iPSCs.

Health-Related Quality of Life in Egyptian Children With Haemophilia A and Chronic Arthropathy With the Era of Emicizumab Therapy: A Single-Centre Cohort Study.

Posterior fossa extradural haematoma with cerebral venous sinus thrombosis precipitates haemophilia a diagnosis: a paediatric case report and literature review.

NXT007 enhances in vitro coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formation.

Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry.